Humacyte Launches Symvess, a Revolutionary Bioengineered Vessel for Trauma Patients

Humacyte, Inc. has officially launched Symvess, a first-in-class bioengineered vessel designed for urgent vascular repair in cases of severe trauma. Following its FDA approval in December 2024, Symvess is now being shipped to hospitals across the U.S., providing a groundbreaking alternative to traditional vein grafts. Unlike conventional procedures that require harvesting a patient’s vein, Symvess is available off-the-shelf, reducing surgical time and eliminating additional injury. Early adoption has been strong, with 21 hospitals already initiating the approval process and several institutions moving forward with purchases.

Dr. Laura Niklason, CEO of Humacyte, highlighted the significance of this milestone, calling it "a new era in vascular surgery and patient care." Symvess has already demonstrated success in both clinical trials and real-world applications, including wartime injuries in Ukraine. Studies show that it improves blood flow, lowers infection risk, and reduces the need for amputations. Humacyte has also introduced a cost-saving model, positioning Symvess as a more efficient and effective option than traditional grafts. With this commercial launch, Humacyte aims to expand access to innovative, life-saving vascular solutions worldwide.